Hsu: AI pharma commercial pitches outpace fundamental research breakthroughs
“I think in many ways the kind of pitch and the framing of these companies precedes The fundamental research capability breakthroughs.”
Hsu: AI for protein design and binding has real-world heft
“There's heft in anything to do with proteins, right? Obviously protein binding, but increasingly in protein design, right? And I think there's real heft there.”
Hsu: Multimodal biological models in AI biotech are currently mostly hype
“And then, you know, where there's hype is in Multimodal biological models, whatever that means, right?”
Hsu: AI will become a native part of drug discovery in years
“I feel like in, you know, I mean, increasingly in just a few years, this will just be a native part of the stack, right? Just like we use You know, the internet and we use phones. We're going to have AI in all parts of the stack, right? And so it's just going …”
Hsu: High-throughput biology is currently limited to imaging and sequencing
“Like, in biology, we ultimately have two ways to study it in high throughput. It's imaging and sequencing, right?”
Hsu: Virtual cell models do not need mechanistic explanations to be useful
“And I would say similarly with a virtual cell model, it may not tell me literally why, just like a alpha fold doesn't tell me literally why did the protein fold this way and how, but it just told me the end state and it was reasonably accurate. I think that wo…”